(Total Views: 933)
Posted On: 02/06/2021 12:29:15 PM
Post# of 145871
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Hello all. I've been lurking on here since back in 2019 when I first invested in Cytodyn. After realizing that the ad popups now have their own ad popups who brought more ad popups to the party, I decided to make an account hoping they back off, but the same gray haired dudes are smirking at me. I know, I'll look at ad blockers. But, since I created an account, why not say hi and let everyone know that there have been tons of us in the background watching this stock for a while now.
Like the dudes in the ads, I normally have a leery look on most stocks, but even through all the craziness of cydy, I've felt optimism. I'm looking forward to a positive result for the CD12 and future trials. From discussions and reading, the science looks on-point.
Anyways, I don't have much to add right now. Maybe a viewpoint from one of the army of outsiders and lurkers.
AF is a fool and everyone seems to realize that now. His hit-piece didn't even dent the stock price, can't even swell a progress or start a scene or two, but no doubt still an easy tool.
Not sure about MDV, never met him, never touched him, not going to touch him now.
The Bruce / Nader thing, maybe going to only discuss lightly. Though I am not a lawyer, I work with patent/copyright lawyers. I asked them about this whole BP/NP thing, which seems to maybe point to technology created while under contract. Specifically, BP's test kits? Maybe technology disputes over patents or something? Many people use patents/tech innovation only for litigation or wonky strong arm techniques. But, we'll see, I'm too far outside to see in. If I find the exact cause of headaches and can run a test for it, I probably can't sue Tylenol and prevent them from selling their product for headaches. So, it's unlikely that being able to verify the cause of a problem being CCL5/RANTES is going to stop a CCR5 inhibitor drug company from continuing to treat the problem.
Stock manipulation on the OTC sucks. We need to get off of this thing. Mulholland needs to get us out of first gear. I'm sure there's a lot to do, so I can't blame him for not succeeding in doing the most important thing for this company's future outside of approvals. We could probably get better funding on Nasdaq, more stability, better control over short-attacks. Hey, Flash, wanna hear a joke?
These ideas of combination therapy are cool, but let's finish the trials we are doing now first. The crew over at Cytodyn have probably written down every possible application, but that doesn't mean there is time nor money until we finish one and get the label.
Nader as CEO. He's a good salesman and knows enough. Could/should he be replaced? Some people on here mention that he doesn't have the deep medical knowledge of the drug. Is that the job of the CEO? Or is it to get the product to market to sell? As CTO and tech lead, I don't expect my CEO crony to know the intricate details of the software, but I do expect him to know enough to sell the hell out of it. It's absurd to require the CEO to be a specialist in the field. Someone with that knowledge would be better suited as CMO. It's funny to entertain the idea, but let's get serious here. You can't split your time like that... that's academia thinking, mock worthy by the real world. The CEO is CEO, CTO is CTO, CMO is CMO, and COO locks up the building for the night.
Future stock price, successes, and failures. If I could successfully forecast these things, I would be a trillionaire. I'm just hanging in there long-term.
FDA for small companies. Unless your job is directly giving them a hand or putting money into their drawers, you probably don't have much sway. You gotta be dirty to hang with that filthy, corrupt bunch. Let's see if the Philippines are more accepting.
I guess that's all for now. Let's see how the results go. Hopefully news soon.
Like the dudes in the ads, I normally have a leery look on most stocks, but even through all the craziness of cydy, I've felt optimism. I'm looking forward to a positive result for the CD12 and future trials. From discussions and reading, the science looks on-point.
Anyways, I don't have much to add right now. Maybe a viewpoint from one of the army of outsiders and lurkers.
AF is a fool and everyone seems to realize that now. His hit-piece didn't even dent the stock price, can't even swell a progress or start a scene or two, but no doubt still an easy tool.
Not sure about MDV, never met him, never touched him, not going to touch him now.
The Bruce / Nader thing, maybe going to only discuss lightly. Though I am not a lawyer, I work with patent/copyright lawyers. I asked them about this whole BP/NP thing, which seems to maybe point to technology created while under contract. Specifically, BP's test kits? Maybe technology disputes over patents or something? Many people use patents/tech innovation only for litigation or wonky strong arm techniques. But, we'll see, I'm too far outside to see in. If I find the exact cause of headaches and can run a test for it, I probably can't sue Tylenol and prevent them from selling their product for headaches. So, it's unlikely that being able to verify the cause of a problem being CCL5/RANTES is going to stop a CCR5 inhibitor drug company from continuing to treat the problem.
Stock manipulation on the OTC sucks. We need to get off of this thing. Mulholland needs to get us out of first gear. I'm sure there's a lot to do, so I can't blame him for not succeeding in doing the most important thing for this company's future outside of approvals. We could probably get better funding on Nasdaq, more stability, better control over short-attacks. Hey, Flash, wanna hear a joke?
These ideas of combination therapy are cool, but let's finish the trials we are doing now first. The crew over at Cytodyn have probably written down every possible application, but that doesn't mean there is time nor money until we finish one and get the label.
Nader as CEO. He's a good salesman and knows enough. Could/should he be replaced? Some people on here mention that he doesn't have the deep medical knowledge of the drug. Is that the job of the CEO? Or is it to get the product to market to sell? As CTO and tech lead, I don't expect my CEO crony to know the intricate details of the software, but I do expect him to know enough to sell the hell out of it. It's absurd to require the CEO to be a specialist in the field. Someone with that knowledge would be better suited as CMO. It's funny to entertain the idea, but let's get serious here. You can't split your time like that... that's academia thinking, mock worthy by the real world. The CEO is CEO, CTO is CTO, CMO is CMO, and COO locks up the building for the night.
Future stock price, successes, and failures. If I could successfully forecast these things, I would be a trillionaire. I'm just hanging in there long-term.
FDA for small companies. Unless your job is directly giving them a hand or putting money into their drawers, you probably don't have much sway. You gotta be dirty to hang with that filthy, corrupt bunch. Let's see if the Philippines are more accepting.
I guess that's all for now. Let's see how the results go. Hopefully news soon.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)